UNICA IRIS Institutional Research Information System

MARONGIU, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 151.141
NA - Nord America 11.655
AS - Asia 5.208
SA - Sud America 923
AF - Africa 207
OC - Oceania 64
Continente sconosciuto - Info sul continente non disponibili 4
Totale 169.202
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 144.194
US - Stati Uniti d'America 11.438
NL - Olanda 3.813
SG - Singapore 1.999
CN - Cina 1.609
BR - Brasile 688
UA - Ucraina 677
SE - Svezia 646
VN - Vietnam 504
DE - Germania 417
GB - Regno Unito 344
FI - Finlandia 341
FR - Francia 255
HK - Hong Kong 219
IN - India 145
CA - Canada 122
KR - Corea 91
BD - Bangladesh 81
AR - Argentina 75
IQ - Iraq 70
MX - Messico 66
ZA - Sudafrica 63
RU - Federazione Russa 57
TR - Turchia 55
AU - Australia 53
JP - Giappone 53
ES - Italia 51
PK - Pakistan 50
AT - Austria 46
ID - Indonesia 44
IE - Irlanda 40
CO - Colombia 39
IR - Iran 37
EC - Ecuador 36
PL - Polonia 36
EG - Egitto 32
BE - Belgio 30
MA - Marocco 29
PH - Filippine 28
MY - Malesia 27
SA - Arabia Saudita 26
RO - Romania 25
UZ - Uzbekistan 22
CH - Svizzera 20
CL - Cile 20
TN - Tunisia 19
VE - Venezuela 19
KE - Kenya 18
TW - Taiwan 18
HU - Ungheria 17
JO - Giordania 17
LT - Lituania 17
PE - Perù 17
ET - Etiopia 15
CZ - Repubblica Ceca 14
PY - Paraguay 14
AE - Emirati Arabi Uniti 13
AL - Albania 13
TH - Thailandia 13
DK - Danimarca 12
BG - Bulgaria 11
IL - Israele 11
NZ - Nuova Zelanda 11
RS - Serbia 11
KZ - Kazakistan 10
NP - Nepal 10
BA - Bosnia-Erzegovina 9
AZ - Azerbaigian 8
DZ - Algeria 8
SD - Sudan 8
GR - Grecia 7
UY - Uruguay 7
BH - Bahrain 6
LB - Libano 6
PT - Portogallo 6
CY - Cipro 5
GE - Georgia 5
NO - Norvegia 5
BY - Bielorussia 4
CR - Costa Rica 4
EE - Estonia 4
JM - Giamaica 4
MK - Macedonia 4
MT - Malta 4
PR - Porto Rico 4
BO - Bolivia 3
CI - Costa d'Avorio 3
GT - Guatemala 3
GY - Guiana 3
HR - Croazia 3
KW - Kuwait 3
LU - Lussemburgo 3
MU - Mauritius 3
NG - Nigeria 3
OM - Oman 3
PA - Panama 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AM - Armenia 2
Totale 169.165
Salva come PNG Salva come JPEG
Città #
Cagliari 140.010
Amsterdam 3.746
Uta 3.426
Fairfield 1.365
Ashburn 953
Singapore 915
Woodbridge 838
Houston 653
Chandler 644
Dallas 626
Seattle 553
San Jose 535
Wilmington 527
Boardman 512
Ann Arbor 463
Cambridge 450
Nyköping 442
Jacksonville 348
Beijing 302
Helsinki 207
Los Angeles 196
Hong Kong 193
The Dalles 175
Dearborn 158
Ho Chi Minh City 153
Lauterbourg 146
Boston 124
Santa Clara 119
Shanghai 117
New York 116
Nanjing 112
Hanoi 99
Council Bluffs 98
Buffalo 89
Hefei 88
San Diego 85
Seoul 73
Milan 67
São Paulo 62
Dong Ket 56
Guangzhou 56
Hebei 55
Toronto 54
Munich 52
Shenyang 49
Rome 47
Redwood City 46
Frankfurt am Main 45
London 45
Redondo Beach 41
Changsha 37
Nanchang 36
Tianjin 36
Jiaxing 34
Orem 33
Nuremberg 32
Vienna 30
Baghdad 29
Chicago 29
Dublin 28
Brussels 27
Rio de Janeiro 27
Verona 27
Johannesburg 26
Atlanta 25
Warsaw 25
Mexico City 24
Tokyo 24
Orange 23
Brandenburg 22
Millbury 22
Da Nang 21
Lahore 21
Brooklyn 20
Chennai 20
Jinan 20
Norwalk 20
Sassari 20
Stockholm 20
Tashkent 20
Denver 19
Haiphong 19
Manchester 19
Phoenix 19
Montreal 17
Mountain View 17
Sydney 17
Turku 17
Bogotá 16
Cape Town 16
Nairobi 16
Redmond 16
Ankara 15
Dhaka 15
Ningbo 15
Zhengzhou 15
Belo Horizonte 14
Paris 14
San Francisco 14
Guayaquil 13
Totale 161.432
Salva come PNG Salva come JPEG
Nome #
Vaping effects on asthma: results from a web survey and clinical investigation 2.974
Sampling variability in hepatic iron concentration in beta-thalassemia 2.871
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.793
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.768
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.751
Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature 2.573
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.564
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.517
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.434
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 2.391
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 2.310
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.297
A retrospective cohort study of patients with pulmonary embolism: The impact of comorbidities on patient's outcome 2.183
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 2.179
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 2.166
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 2.155
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 2.071
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.017
Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability - A Review 2.011
A Sardinian Family with Factor XI Deficiency 1.997
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 1.949
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.884
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.878
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.809
The hemostatic system. 1st Part 1.806
Fibrinogen and D-dimer levels in autoimmune subclinical and overt hypothyroidism and effects of levothyroxine treatment. 1.752
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.743
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.700
Point-of-care testing INR: an overview 1.681
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.661
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.654
Uneven hepatic iron and phosphorus distribution in b-thalassemia 1.650
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.649
Optimizing tailored DIEP flap insetting in unilateral immediate free autologous breast reconstruction 1.642
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.574
Direct oral anticoagulants: what can we learn? 1.568
Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections 1.565
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.564
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.512
T lymphocyte subsets and viral infections in Sardinian parenteral drug abusers: relationship to HIV infection 1.484
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.481
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.454
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 1.445
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.392
[Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections]. FT Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell'eroina e con altre infezioni virali. 1.368
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 1.366
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.348
A guide to oral anticoagulation 1.326
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA(2)DS(2)VASc 1 or 2): a treatment dilemma 1.286
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.285
The Italian START-Register on anticoagulation with focus on atrial fibrillation 1.266
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.251
Heparins and 2019-nCoV infection: a narrative review 1.243
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 1.227
Thyroid disorders and hypocoagulability 1.183
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.179
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 1.148
Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell’eroina e con altre infezioni virali 1.133
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 1.129
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 1.124
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 1.084
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago 1.082
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 1.076
Rheumatoid arthritis and thrombosis 1.073
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 1.065
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 1.010
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 1.007
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 1.002
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 1.001
Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission 992
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 988
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 980
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 939
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal 925
Center-related determinants of VKA anticoagulation quality: A prospective, multicenter evaluation 911
Aortic vulnerability to COVID-19: Is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature 883
Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: The evidence from histology and scanning electron microscopy 880
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature 836
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes 833
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency 832
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 830
Amoxicillina-acido clavulanico ed anticoagulanti orali:un’associazione potenzialmente pericolosa 824
null 824
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab 821
Start-register (Survey on anticoagulated patients register): the first year of activity 788
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 777
null 772
Management of special conditions in patients on vitamin K antagonists 734
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 730
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 689
null 679
Special indications for vitamin K antagonists: a review 674
null 644
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study 640
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 634
null 633
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) 629
null 617
null 616
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2(V617F) mutation 611
Totale 140.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 233.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 233.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216.013 0 0 0 0 0 0 0 0 0 2.136 1.868 2.009
2021/20229.067 879 677 410 654 750 715 606 496 695 941 1.137 1.107
2022/202314.010 1.313 1.842 1.695 1.232 1.226 1.485 702 1.126 916 789 1.047 637
2023/202416.132 678 938 781 1.401 1.612 2.201 2.427 1.093 778 1.179 1.611 1.433
2024/202528.713 6.080 7.329 3.416 2.935 3.253 1.830 2.131 175 431 433 291 409
2025/202612.531 552 369 1.243 1.020 719 610 1.739 592 4.482 1.205 0 0
Totale 169.755